consultancy

Jan 02, 2018

British scientists looking forward to treat Alzheimer’s disease through diabetes drug A group of British scientists are looking for the treatment of Alzheimer’s disease in an unlikely source i.e. a drug used for treating Type 2 Diabetes. The team, from Lancaster University, has reported that an experimental three-p...

Dec 07, 2017

AbbVie aims for best-in-class psoriasis prospect The last few years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class product may still be on its way. AbbVie prospect risankizumab showed it could bring 47% of patients to complete skin clearance by week 16 of treatment in a pha...

Dec 05, 2017

KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms Neurocrine Biosciences, Inc. announced new long-term data from the KINECT 4 Phase III open-label study demonstrate that once-daily INGREZZA® (valbenazine) capsules, the first FDA approved treatment for adults with tardive dyskinesi...

Dec 04, 2017

Toll-like receptors are a family of various related proteins that play a major role in the development and defense of plants and animals. These receptors were first discovered in Drosophila melanogaster in the late 20th century which later led to the identification of mammalian homologs. Human TLR family consists of...

Nov 28, 2017

Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The company is examining the safety and efficacy of Rimegepant for the treatment of Mi...

Nov 15, 2017

One of the top five risks for human health includes poor air quality, while the others are blood pressure, smoking tobacco, diabetes, and obesity. The poor air quality has contributed to around 8% of deaths around the world, according to a 2015 statistic and long-term exposure has created health hazard risks such as...

Nov 14, 2017

Novartis ventures itself into developing new editing technology Novartis has moved beyond CRISPR and CAR-T gene editing technology with its latest deal with Homology Medicines, aiming to improve upon its R&D work in the arena of cell and gene therapy. The deal involves Novartis using the gene editing technology ...